Safety data from 1009 heart transplant recipients ( n = 214 , receiving azathioprine ; n = 84 , mycophenolate mofetil ( MMF ) ; n = 711 , everolimus ) were reviewed in a post hoc analysis from three randomized , multicenter studies-B253 ( n = 634 ) , A2403 ( n = 199 ) , and A2411 ( n = 176 ) - in which de novo patients received fixed-dose or concentration-controlled everolimus ( target trough , 3-8 ng/mL ) , azathioprine , or MMF with standard - or reduced-exposure cyclosporine A. Incisional complications were analyzed for incidence , type , and severity up to day 90 posttransplant .
